ANAB 股價走勢圖
ANAB 股票價格預測
AnaptysBio Inc
$67.36
-2.77%
$-1.92
收盤價：May 06, 16:00:00 GMT-4
$66.95
-0.6%
$-0.4
盤後：May 06, 20:00:00 GMT-4
返回
AnaptysBio Inc (ANAB) 股票價格預測
關鍵數據
前收市價
$69.28
開盤價
$69.84
當日範圍
$66.95 - $72.22
52週區間
$17.1 - $73.3
交易量
680.9K
平均成交量
566.0K
股息收益率
--
每股盈餘 (TTM)
-0.32
市值
$1.9B
什麼是 ANAB？
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
